Latest immunotherapies Stories
MAINZ, Germany, April 22, 2015 /PRNewswire/ -- Potential for truly personalized treatment of any cancer BioNTech AG [http://www.biontech.de
MARLBOROUGH, Mass., March 27, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII) and privately-held MirImmune LLC, today announced that they have entered into an exclusive license
NantCell To Acquire Exclusive Rights to Antibodies Including CAR-TNK(TM) Products and the Checkpoint Inhibitors PD-1 and PD-L1 SAN DIEGO, Mar.
LAKE FOREST, Calif., March 11, 2015 /PRNewswire/ -- Cryoport, Inc.
ALBUQUERQUE, N.M., Feb. 17, 2015 /PRNewswire/ -- Agilvax, Inc.
Dr. Gelder's Accomplishments Include Successful Development of Cancer Therapies at Pfizer, Wyeth and Bayer PLYMOUTH MEETING, Pa., Jan.
Initiation of Registrational Studies Planned for This Year MORRISTOWN, N.J., Jan.
Lead Immunotherapy Product Candidate GEN-1 to Enter Dose Escalating Clinical Study in the Second Half of 2015 LAWRENCEVILLE, N.J., Jan.
ORLANDO, Fla., Jan. 5, 2015 /PRNewswire/ -- Immune Therapeutics Inc.
- A serpent whose bite was fabled to produce intense thirst.